IGHG3 and neoplasm: In our prior studies, a prototypic αHER2 IgG3-huEndo-P125A fusion protein demonstrated 40–50-fold longer half-life in mice compared to endostatin, superior anti-angiogenic efficacy, and enhanced anti-tumor activity in vivo [15,16].